Ana S. Leal

Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer

Ana S. Leal, Charlotte R. Williams, Darlene B. Royce et al. · Cancer Letters · 2017 · 119 citations

Tumor Biology, Potential Therapies, Pancreatic Cancer +7

Synthesis of novel ursolic acid heterocyclic derivatives with improved abilities of antiproliferation and induction of p53, p21waf1 and NOXA in pancreatic cancer cells

Ana S. Leal, Rui Wang, Jorge A. R. Salvador et al. · Bioorganic & Medicinal Chemistry · 2012 · 66 citations

Tumor Biology, Pancreatic Cancer, Chemoprevention Strategy +9

A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice

Di Zhang, Paige Baldwin, Ana S. Leal et al. · Theranostics · 2019 · 64 citations · Full text

Synthesis of novel heterocyclic oleanolic acid derivatives with improved antiproliferative activity in solid tumor cells

Ana S. Leal, Rui Wang, Jorge A. R. Salvador et al. · Organic & Biomolecular Chemistry · 2013 · 35 citations

Engineering, N-alkylimidazole 27, Organic Chemistry +19

Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models

Ana S. Leal, Kayla Zydeck, Sarah Carapellucci et al. · npj Breast Cancer · 2019 · 32 citations · Full text